MX2023002900A - Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-aceta mida como inhibidores del receptor i del factor de crecimiento transformante beta/cinasa 5 similar al receptor de activina (alk5). - Google Patents
Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-aceta mida como inhibidores del receptor i del factor de crecimiento transformante beta/cinasa 5 similar al receptor de activina (alk5).Info
- Publication number
- MX2023002900A MX2023002900A MX2023002900A MX2023002900A MX2023002900A MX 2023002900 A MX2023002900 A MX 2023002900A MX 2023002900 A MX2023002900 A MX 2023002900A MX 2023002900 A MX2023002900 A MX 2023002900A MX 2023002900 A MX2023002900 A MX 2023002900A
- Authority
- MX
- Mexico
- Prior art keywords
- alk5
- growth factor
- transforming growth
- quinolin
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382861.1A EP3978487A1 (en) | 2020-09-30 | 2020-09-30 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| PCT/EP2021/076730 WO2022069509A1 (en) | 2020-09-30 | 2021-09-29 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002900A true MX2023002900A (es) | 2023-05-25 |
Family
ID=72744716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002900A MX2023002900A (es) | 2020-09-30 | 2021-09-29 | Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-aceta mida como inhibidores del receptor i del factor de crecimiento transformante beta/cinasa 5 similar al receptor de activina (alk5). |
Country Status (20)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022010251A2 (pt) | 2019-11-28 | 2022-09-06 | Origo Biopharma S L | Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta |
| WO2026017797A1 (en) | 2024-07-17 | 2026-01-22 | Agomab Spain S.L.U. | Crystalline forms |
| WO2026082960A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | 1,5-naphtyridine and quinoline based inhibitors of alk5 |
| WO2026082968A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | Novel compounds |
| CN121554469B (zh) * | 2026-01-23 | 2026-04-17 | 四川大学华西医院 | 一种alk5 protac化合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ501112A (en) * | 1997-05-22 | 2002-10-25 | G | Substituted pyrazoles as p38 kinase inhibitors |
| US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| ATE291020T1 (de) * | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| WO2004026306A2 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| WO2004026302A1 (en) | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| JP2009500419A (ja) * | 2005-07-05 | 2009-01-08 | アリックス セラピューティクス、インコーポレイテッド | 立体異性体のピリジル及びピリドニル化合物並びに消化管障害及び中枢神経系障害の治療方法 |
| CN102056907B (zh) * | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| WO2011076725A1 (en) | 2009-12-21 | 2011-06-30 | Bayer Cropscience Ag | Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi |
| RU2612958C2 (ru) * | 2011-07-13 | 2017-03-14 | Ск Кемикалз Ко., Лтд. | 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4 |
| IN2014CN02805A (cg-RX-API-DMAC7.html) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| JP2021518855A (ja) | 2018-03-02 | 2021-08-05 | ユニヴェルシテ ド ローザンヌ | Wntシグナル伝達経路阻害剤としてのピラゾール誘導体 |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| CN110433164A (zh) | 2019-08-15 | 2019-11-12 | 南开大学 | TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用 |
| BR112022010251A2 (pt) | 2019-11-28 | 2022-09-06 | Origo Biopharma S L | Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta |
-
2020
- 2020-09-30 EP EP20382861.1A patent/EP3978487A1/en not_active Withdrawn
-
2021
- 2021-09-17 AR ARP210102591A patent/AR123543A1/es unknown
- 2021-09-29 IL IL301663A patent/IL301663B2/en unknown
- 2021-09-29 BR BR112023004612A patent/BR112023004612A2/pt unknown
- 2021-09-29 AU AU2021353965A patent/AU2021353965A1/en active Pending
- 2021-09-29 JP JP2023519608A patent/JP7752684B2/ja active Active
- 2021-09-29 MX MX2023002900A patent/MX2023002900A/es unknown
- 2021-09-29 RS RS20260828A patent/RS68301B1/en unknown
- 2021-09-29 US US18/246,903 patent/US12577230B2/en active Active
- 2021-09-29 KR KR1020237008242A patent/KR20230079027A/ko active Pending
- 2021-09-29 LT LTEPPCT/EP2021/076730T patent/LT4222149T/lt unknown
- 2021-09-29 PH PH1/2023/550777A patent/PH12023550777A1/en unknown
- 2021-09-29 CN CN202180066883.4A patent/CN116323601B/zh active Active
- 2021-09-29 EP EP26171404.2A patent/EP4781988A2/en active Pending
- 2021-09-29 WO PCT/EP2021/076730 patent/WO2022069509A1/en not_active Ceased
- 2021-09-29 EP EP21786169.9A patent/EP4222149B1/en active Active
- 2021-09-29 FI FIEP21786169.9T patent/FI4222149T3/fi active
- 2021-09-29 PT PT217861699T patent/PT4222149T/pt unknown
- 2021-09-29 ES ES21786169T patent/ES3029607T3/es active Active
- 2021-09-29 CA CA3196108A patent/CA3196108A1/en active Pending
- 2021-09-29 DK DK21786169.9T patent/DK4222149T3/da active
-
2023
- 2023-02-23 ZA ZA2023/02393A patent/ZA202302393B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230373966A1 (en) | 2023-11-23 |
| KR20230079027A (ko) | 2023-06-05 |
| FI4222149T3 (fi) | 2026-07-16 |
| EP4222149B1 (en) | 2026-05-06 |
| AR123543A1 (es) | 2022-12-14 |
| ES3029607T3 (es) | 2026-06-23 |
| EP4781988A2 (en) | 2026-07-29 |
| LT4222149T (lt) | 2026-08-10 |
| AU2021353965A1 (en) | 2023-04-27 |
| CN116323601A (zh) | 2023-06-23 |
| IL301663A (en) | 2023-05-01 |
| PH12023550777A1 (en) | 2023-11-20 |
| RS68301B1 (en) | 2026-07-31 |
| ES3029607T1 (en) | 2025-06-24 |
| CA3196108A1 (en) | 2022-04-07 |
| ZA202302393B (en) | 2026-03-25 |
| CN116323601B (zh) | 2026-05-12 |
| EP3978487A1 (en) | 2022-04-06 |
| IL301663B2 (en) | 2026-05-01 |
| WO2022069509A1 (en) | 2022-04-07 |
| PT4222149T (pt) | 2026-06-03 |
| JP2023544716A (ja) | 2023-10-25 |
| BR112023004612A2 (pt) | 2023-04-11 |
| AU2021353965A9 (en) | 2024-08-01 |
| US12577230B2 (en) | 2026-03-17 |
| EP4222149A1 (en) | 2023-08-09 |
| JP7752684B2 (ja) | 2025-10-10 |
| IL301663B1 (en) | 2026-01-01 |
| DK4222149T3 (da) | 2026-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023550777A1 (en) | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2023007218A (es) | Cocristal de un inhibidor de cinasa dependiente de ciclina (cdk). | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| CR20200263A (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| WO2019168688A3 (en) | Quinolone analogs and their salts, compositions, and method for their use | |
| MX2023010087A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| MY206262A (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| ZA202205149B (en) | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| WO2022268935A3 (en) | Process for the preparation of nlrp3 inhibitors | |
| MX2023010083A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| PH12022551429A1 (en) | Compound and composition as pdgf receptor kinase inhibitor | |
| MX2025011499A (es) | Forma de cristal de sal de compuesto de anillo fusionado cuaternario, y método de preparación y uso del mismo | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| AU2021260669A8 (en) | A formulation for treating ophthalmic conditions | |
| MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). |